<table id="table5" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5: Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Trials or Predicted Interaction [See<linkhtml href="#S12.3"> Clinical Pharmacology (12.3)</linkhtml> (<linkhtml href="#table6">Tables 6 </linkhtml>and<linkhtml href="#table7"> 7</linkhtml>) for Magnitude of Interaction.]</caption>
<col align="left" valign="top" width="15%"></col>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="65%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Concomitant Drug Class:<br/>Drug Name</th>
<th stylecode="Rrule">Effect on concentration of INCIVEK or Concomitant Drug</th>
<th stylecode="Rrule">Clinical Comment</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">The direction of the arrow (↑ <content stylecode="italics">= increase,</content> ↓ <content stylecode="italics">= decrease,</content> ↔ <content stylecode="italics">= no change</content>) indicates the direction of the change in PK.</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIARRHYTHMICS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">lidocaine (systemic), amiodarone, bepridil, flecainide, propafenone, quinidine<br/>
</td>
<td stylecode="Rrule">↑ antiarrhythmics</td>
<td stylecode="Rrule">Co-administration with telaprevir has the potential to produce serious and/or life-threatening adverse events and has not been studied. Caution is warranted and clinical monitoring is recommended when co-administered with telaprevir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">digoxin<footnote id="table5a">These interactions have been studied. See <content stylecode="italics">
<linkhtml href="#S12.3">Clinical Pharmacology (12.3)</linkhtml>,</content>
<linkhtml href="#table6"> Tables 6</linkhtml> and<linkhtml href="#table7"> 7</linkhtml>.</footnote>
</td>
<td stylecode="Rrule">↑ digoxin<br/>
</td>
<td stylecode="Rrule">Concentrations of digoxin were increased when co-administered with telaprevir. The lowest dose of digoxin should be initially prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIBACTERIALS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">clarithromycin<br/>erythromycin<br/>telithromycin</td>
<td stylecode="Rrule">↑ telaprevir<br/>↑ antibacterials</td>
<td stylecode="Rrule">Concentrations of both telaprevir and the antibacterial may be increased during co-administration. Caution is warranted and clinical monitoring is recommended when co-administered with telaprevir. QT interval prolongation and Torsade de Pointes have been reported with clarithromycin and erythromycin. QT interval prolongation has been reported with telithromycin.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTICOAGULANT</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">warfarin</td>
<td stylecode="Rrule">↑ or ↓ warfarin</td>
<td stylecode="Rrule">Concentrations of warfarin may be altered when co-administered with telaprevir. The international normalized ratio (INR) should be monitored when warfarin is co-administered with telaprevir.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTICONVULSANTS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">carbamazepine<br/>phenobarbital<br/>phenytoin</td>
<td stylecode="Rrule">↓ telaprevir<br/>↑ carbamazepine<br/>↑ or ↓ phenytoin<br/>↑ or ↓ phenobarbital<br/>
</td>
<td stylecode="Rrule">Concentrations of the anticonvulsant may be altered and concentrations of telaprevir may be decreased. Caution should be used when prescribing carbamazepine, phenobarbital, and phenytoin.<br/>Telaprevir may be less effective in patients taking these agents concomitantly.<br/>Clinical or laboratory monitoring of carbamazepine, phenobarbital, and phenytoin concentrations and dose titration are recommended to achieve the desired clinical response.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIDEPRESSANTS</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">escitalopram<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↔ telaprevir<br/>↓ escitalopram</td>
<td stylecode="Rrule">Concentrations of escitalopram were decreased when co-administered with telaprevir. Selective serotonin reuptake inhibitors such as escitalopram have a wide therapeutic index, but doses may need to be adjusted when combined with telaprevir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">trazodone</td>
<td stylecode="Rrule">↑ trazodone</td>
<td stylecode="Rrule">Concomitant use of trazodone and telaprevir may increase plasma concentrations of trazodone which may lead to adverse events such as nausea, dizziness, hypotension and syncope. If trazodone is used with telaprevir, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIFUNGALS</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">ketoconazole<footnoteref idref="table5a"></footnoteref>
<br/>itraconazole<br/>posaconazole<br/>voriconazole</td>
<td stylecode="Rrule">↑ ketoconazole<br/>↑ telaprevir<br/>
<br/>↑ itraconazole<br/>↑ posaconazole<br/>↑ or ↓ voriconazole</td>
<td stylecode="Rrule">Ketoconazole increases the plasma concentrations of telaprevir. Concomitant systemic use of itraconazole or posaconazole with telaprevir may increase plasma concentration of telaprevir.<br/>Plasma concentrations of itraconazole, ketoconazole, or posaconazole may be increased in the presence of telaprevir. When co-administration is required, high doses of itraconazole or ketoconazole (greater than 200 mg/day) are not recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Caution is warranted and clinical monitoring is recommended for itraconazole, posaconazole and voriconazole.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">QT interval prolongation and Torsade de Pointes have been reported with voriconazole and posaconazole. QT interval prolongation has been reported with ketoconazole.<br/>Due to multiple enzymes involved with voriconazole metabolism, it is difficult to predict the interaction with telaprevir. Voriconazole should not be administered to patients receiving telaprevir unless an assessment of the benefit/risk ratio justifies its use.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTI GOUT</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">colchicine</td>
<td stylecode="Rrule">↑ colchicine</td>
<td stylecode="Rrule">Patients with renal or hepatic impairment should not be given colchicine with telaprevir, due to the risk of colchicine toxicity. A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function.<br/>
<content stylecode="underline">Treatment of gout flares: co-administration of colchicine in patients on telaprevir: </content>
<br/>0.6 mg (1 tablet) for 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Not to be repeated before 3 days.<br/>
<content stylecode="underline">If used for prophylaxis of gout flares: co-administration of colchicine in patients on telaprevir:</content>
<br/>If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br/>If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<br/>
<content stylecode="underline">Treatment of familial Mediterranean fever (FMF): co-administration of colchicine in patients on telaprevir:</content>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIMYCOBACTERIAL</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">rifabutin</td>
<td stylecode="Rrule">↓ telaprevir<br/>↑ rifabutin</td>
<td stylecode="Rrule">Concentrations of telaprevir may be decreased, while rifabutin concentrations may be increased during co-administration. Telaprevir may be less effective due to decreased concentrations. The concomitant use of rifabutin and telaprevir is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">BENZODIAZEPINES</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">alprazolam<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↑ alprazolam</td>
<td stylecode="Rrule">Concomitant use of alprazolam and telaprevir increases exposure to alprazolam. Clinical monitoring is warranted.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">parenterally<br/>administered<br/>midazolam<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↑ midazolam</td>
<td stylecode="Rrule">Concomitant use of parenterally administered midazolam with telaprevir increased exposure to midazolam. Co-administration should be done in a setting which ensures clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.<br/>Dose reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Co-administration of oral midazolam with telaprevir is contraindicated.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">zolpidem (non-benzodiazepine sedative)<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↓ zolpidem</td>
<td stylecode="Rrule">Exposure to zolpidem was decreased when co-administered with telaprevir. Clinical monitoring and dose titration of zolpidem is recommended to achieve the desired clinical response.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">CALCIUM CHANNEL BLOCKERS</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">amlodipine<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↑ amlodipine</td>
<td stylecode="Rrule">Exposure to amlodipine was increased when co-administered with telaprevir. Caution should be used and dose reduction for amlodipine should be considered. Clinical monitoring is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">diltiazem<br/>felodipine<br/>nicardipine<br/>nifedipine<br/>nisoldipine<br/>verapamil</td>
<td stylecode="Rrule">↑calcium channel blockers</td>
<td stylecode="Rrule">Concentrations of other calcium channel blockers may be increased when telaprevir is co-administered.<br/>Caution is warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">CORTICOSTEROIDS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Systemic</content>
<br/>prednisone<br/>methylprednisolone </td>
<td stylecode="Rrule">↑ prednisone<br/>↑ methylprednisolone</td>
<td stylecode="Rrule">Systemic corticosteroids such as prednisone and methylprednisolone are CYP3A substrates. Since telaprevir is a strong CYP3A inhibitor, plasma concentrations of these corticosteroids can be increased significantly. Co-administration of systemic corticosteroids and telaprevir is not recommended [<content stylecode="italics">see 													<linkhtml href="#S5.1"> Warnings and Precautions (5.1)</linkhtml>
</content>].</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Systemic </content>
<br/>dexamethasone</td>
<td stylecode="Rrule">↓ telaprevir<br/>
</td>
<td stylecode="Rrule">Systemic dexamethasone induces CYP3A and can thereby decrease telaprevir plasma concentrations. This may result in loss of therapeutic effect of telaprevir. Therefore this combination should be used with caution or alternatives should be considered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="italics">Inhaled/Nasal</content>
<br/>fluticasone<br/>budesonide</td>
<td stylecode="Rrule">↑fluticasone<br/>↑ budesonide<br/>
</td>
<td stylecode="Rrule">Concomitant use of inhaled fluticasone or budesonide and telaprevir may increase plasma concentrations of fluticasone or budesonide resulting in significantly reduced serum cortisol concentrations. Co-administration of fluticasone or budesonide and telaprevir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ENDOTHELIN RECEPTOR ANTAGONIST</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">bosentan</td>
<td stylecode="Rrule">↑ bosentan</td>
<td stylecode="Rrule">Concentrations of bosentan may be increased when co-administered with telaprevir. Caution is warranted and clinical monitoring is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-ANTIVIRAL AGENTS: HIV-PROTEASE INHIBITORS (PIs)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">atazanavir/ritonavir<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↓ telaprevir<br/>↑ atazanavir<br/>
</td>
<td stylecode="Rrule">Concomitant administration of telaprevir and atazanavir/ritonavir resulted in reduced steady-state telaprevir exposure, while steady-state atazanavir exposure was increased.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">darunavir/ritonavir<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↓ telaprevir<br/>↓ darunavir<br/>
</td>
<td stylecode="Rrule">Concomitant administration of telaprevir and darunavir/ritonavir resulted in reduced steady-state exposures to telaprevir and darunavir. It is not recommended to co-administer darunavir/ritonavir and telaprevir.<br/>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">fosamprenavir/ritonavir<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↓ telaprevir<br/>↓ fosamprenavir<br/>
</td>
<td stylecode="Rrule">Concomitant administration of telaprevir and fosamprenavir/ritonavir resulted in reduced steady-state exposures to telaprevir and amprenavir. It is not recommended to co-administer fosamprenavir/ritonavir and telaprevir.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">lopinavir/ritonavir<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↓ telaprevir<br/>↔ lopinavir<br/>
</td>
<td stylecode="Rrule">Concomitant administration of telaprevir and lopinavir/ritonavir resulted in reduced steady-state telaprevir exposure, while the steady-state exposure to lopinavir was not affected. It is not recommended to co-administer lopinavir/ritonavir and telaprevir.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">efavirenz<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↓ telaprevir<br/>↓ efavirenz</td>
<td stylecode="Rrule">Concomitant administration of telaprevir and efavirenz resulted in reduced steady-state exposures to telaprevir and efavirenz.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">tenofovir disoproxil fumarate<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↔ telaprevir<br/>↑ tenofovir<br/>
</td>
<td stylecode="Rrule">Concomitant administration of telaprevir and tenofovir disoproxil fumarate resulted in increased tenofovir exposure. Increased clinical and laboratory monitoring are warranted. Tenofovir disoproxil fumarate should be discontinued in patients who develop tenofovir-associated toxicities.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA REDUCTASE INHIBITORS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">atorvastatin<footnoteref idref="table5a"></footnoteref>
<br/>fluvastatin<br/>pitavastatin<br/>pravastatin<br/>rosuvastatin</td>
<td stylecode="Rrule">↑ statin</td>
<td stylecode="Rrule">Plasma concentrations of atorvastatin are markedly increased when co-administered with telaprevir. Avoid concomitant administration of telaprevir and atorvastatin. For fluvastatin, pitavastatin, pravastatin, and rosuvastatin, caution is warranted and clinical monitoring is recommended. Refer to <content stylecode="italics">
<linkhtml href="#S4">Contraindications (4) </linkhtml>
</content>for HMG-CoA reductase inhibitors (lovastatin, simvastatin) that are contraindicated with INCIVEK.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HORMONAL CONTRACEPTIVES/ESTROGEN</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">ethinyl estradiol<footnoteref idref="table5a"></footnoteref>
<br/>norethindrone</td>
<td stylecode="Rrule">↓ ethinyl estradiol<br/>↔ norethindrone<br/>
</td>
<td stylecode="Rrule">Exposure to ethinyl estradiol was decreased when co-administered with telaprevir. Two effective non-hormonal methods of contraception should be used during treatment with telaprevir.<br/>Patients using estrogens as hormone replacement therapy should be clinically monitored for signs of estrogen deficiency. Refer also to <content stylecode="italics">
<linkhtml href="#S4">Contraindications (4)</linkhtml>
</content>, <content stylecode="italics">
<linkhtml href="#S5.3">Warnings and Precautions (5.3)</linkhtml>
</content>, <content stylecode="italics">
<linkhtml href="#S8.1">Use in Specific Populations (8.1)</linkhtml>
</content>, and <content stylecode="italics">
<linkhtml href="#S17.2">Patient Counseling Information (17.2)</linkhtml>
</content>.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">IMMUNOSUPPRESSANTS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">cyclosporine<footnoteref idref="table5a"></footnoteref>
<br/>sirolimus<br/>tacrolimus<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↑ cyclosporine<br/>↑ sirolimus<br/>↑ tacrolimus<br/>
</td>
<td stylecode="Rrule">Plasma concentrations of cyclosporine and tacrolimus are markedly increased when co-administered with telaprevir. Plasma concentration of sirolimus may be increased when co-administered with telaprevir, though this has not been studied. Significant dose reductions and prolongation of the dosing interval of the immunosuppressant to achieve the desired blood levels should be anticipated. Close monitoring of the immunosuppressant blood levels, and frequent assessments of renal function and immunosuppressant-related side effects are recommended when co-administered with telaprevir. Tacrolimus may prolong the QT interval. The use of telaprevir in organ transplant patients has not been studied.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">INHALED BETA AGONIST</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">salmeterol</td>
<td stylecode="Rrule">↑ salmeterol</td>
<td stylecode="Rrule">Concentrations of salmeterol may be increased when co-administered with telaprevir. Concurrent administration of salmeterol and telaprevir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">INSULIN SECRETAGOGUES </content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">repaglinide</td>
<td stylecode="Rrule">↑ repaglinide</td>
<td stylecode="Rrule">Caution is warranted and clinical monitoring is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">NARCOTIC ANALGESIC</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">methadone<footnoteref idref="table5a"></footnoteref>
</td>
<td stylecode="Rrule">↓ R-methadone<br/>
</td>
<td stylecode="Rrule">Concentrations of methadone were reduced when co-administered with telaprevir. No adjustment of methadone dose is required when initiating co-administration of telaprevir. However, clinical monitoring is recommended as the dose of methadone during maintenance therapy may need to be adjusted in some patients.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">PDE5 INHIBITORS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">sildenafil<br/>tadalafil<br/>vardenafil</td>
<td stylecode="Rrule">↑ PDE5 inhibitors</td>
<td stylecode="Rrule">Concentrations of PDE5 inhibitors may be increased when co-administered with telaprevir. For the treatment of erectile dysfunction, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg dose in 72 hours, or tadalafil at a single dose not exceeding 10 mg dose in 72 hours can be used with increased monitoring for PDE5 inhibitor-associated adverse events.<br/>QT interval prolongation has been reported with vardenafil. Caution is warranted and clinical monitoring is recommended.<br/>Co-administration of sildenafil or tadalafil and telaprevir in the treatment of pulmonary arterial hypertension is contraindicated [<content stylecode="italics">see 													<linkhtml href="#S4"> Contraindications (4)</linkhtml>
</content>].</td>
</tr>
</tbody>
</table>